Get the Stockscreener App
347.07
1.01%
3.47
After Hours:
347.95
0.88
+0.25%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $347.07, with a volume of 3.02M.
It is up +1.01% in the last 24 hours and up +4.73% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$343.60
Open:
$344.145
24h Volume:
3.02M
Relative Volume:
1.12
Market Cap:
$186.89B
Revenue:
$35.89B
Net Income/Loss:
$7.01B
P/E Ratio:
26.83
EPS:
12.9352
Net Cash Flow:
$11.54B
1W Performance:
+5.16%
1M Performance:
+4.73%
6M Performance:
+13.54%
1Y Performance:
+26.93%
1-Day Range:
$342.14
$349.98
1-Week Range:
$321.71
$349.98
52-Week Range:
$261.43
$349.98
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
347.07 | 185.02B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,087.38 | 965.30B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.49 | 525.25B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
218.11 | 382.02B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
145.00 | 278.44B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.23 | 263.59B | 46.69B | 15.29B | 9.25B | 3.4329 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen (AMGN) Faces 340B Lawsuit: What Does Sagebrush Dispute Reveal About Its Stakeholder Strategy? - Yahoo Finance
Amgen Faces 340B Lawsuit Spotlighting Drug Pricing And Investor Risks - simplywall.st
Amgen (AMGN) expands obesity strategy with Ro collaboration on GLP-1 therapies - MSN
Amgen (NASDAQ:AMGN) Hits New 1-Year HighHere's Why - MarketBeat
Amgen: A Buy In 2026 On Exciting MariTide ObesityT2D Potential (NASDAQ:AMGN) - Seeking Alpha
Amgen stock hits 52-week high at $346.41 - Investing.com
Sagebrush sues Amgen over 340B program row - The Pharma Letter
Rakuten Investment Management Inc. Purchases Shares of 27,258 Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Downgraded by Bernstein on Market Challenges - GuruFocus
Ember LifeSciences Taps Former Amgen Exec as CFO - Contract Pharma
Amgen downgraded at Bernstein on 2026 outlook - MSN
Cell and Gene Therapy Market Innovations and Key Players: Amgen - openPR.com
Johnson & Johnson Clears the Patent Cliff as 2026 Guidance Resets the Narrative - Investing.com
Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference - The AI Journal
Amgen (AMGN) Expands Obesity Strategy With Ro Collaboration on GLP-1 Therapies - Finviz
Amgen's (NASDAQ:AMGN) Shareholders Will Receive A Bigger Dividend Than Last Year - simplywall.st
Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.52 - Yahoo Finance
AMGEN INC (NASDAQ:AMGN) Shows High Technical and Setup Ratings for Potential Breakout - Chartmill
Arkadios Wealth Advisors Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Red Biotechnology Market Is Going to Boom 20262023 |Amgen Inc., Gilead Sciences, Inc., Biogen - openPR.com
Lobbying Update: $3,550,000 of AMGEN INC lobbying was just disclosed - Quiver Quantitative
Sagebrush Health Sues Amgen for Over $7 Million in Damages - Intellectia AI
Amgen (AMGN) Downgraded by Bernstein, Price Target Unchanged | A - GuruFocus
Bernstein downgrades Amgen as 2026 lacks near-term catalysts - Investing.com
Sanford C. Bernstein Downgrades Amgen (NASDAQ:AMGN) to Market Perform - MarketBeat
Seizert Capital Partners LLC Trims Stock Position in Amgen Inc. $AMGN - MarketBeat
Pacific Heights Asset Management LLC Has $23.99 Million Holdings in Amgen Inc. $AMGN - MarketBeat
UPS building massive $6 million cooler - The Business Journals
40 Under 40: Melissa Wagner, Amgen - Medical Marketing and Media
A Look At Amgen (AMGN) Valuation After Strong Q3 Results And Pipeline Momentum - Yahoo Finance
Amgen stock hits pause on MLK Day — what to watch before AMGN returns Tuesday - TechStock²
Tradewinds LLC. Makes New $988,000 Investment in Amgen Inc. $AMGN - MarketBeat
Amgen Inc.'s (NASDAQ:AMGN) Intrinsic Value Is Potentially 93% Above Its Share Price - 富途资讯
Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus - Yahoo Finance
Royal Fund Management LLC Cuts Holdings in Amgen Inc. $AMGN - MarketBeat
3,785 Shares in Amgen Inc. $AMGN Bought by Campbell & CO Investment Adviser LLC - MarketBeat
Allstate Corp Has $5.54 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
DISCO Oncology Pact And MariTide Obesity Data Might Change The Case For Investing In Amgen (AMGN) - simplywall.st
Sequoia Financial Advisors LLC Has $45.33 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (NASDAQ:AMGN) is largely controlled by institutional shareholders who own 80% of the company - Yahoo Finance
Amgen’s Obesity Drug May Crush Novo Nordisk & Lilly With Just Four Shots A Year! - Smartkarma
WoodTrust Financial Corp Sells 588,232 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Position Cut by QRG Capital Management Inc. - MarketBeat
Pinnacle Financial Partners Inc Has $13.66 Million Stake in Amgen Inc. $AMGN - MarketBeat
Assessing Amgen (AMGN) Valuation As Shares Track Close To Analyst Targets - simplywall.st
Lobbying Update: $60,000 of AMGEN INC. FKA HORIZON THERAPEUTICS USA INC. lobbying was just disclosed - Quiver Quantitative
Wright Investors Service Inc. Has $2.76 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen’s Stock Under the Microscope: Modest Drop, Rising Expectations and Fresh Biotech Catalysts - AD HOC NEWS
Amgen Inc. (NASDAQ:AMGN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is Amgen (AMGN) Still Attractive After A 26% One Year Share Price Gain - simplywall.st
Amgen Teases Phase 2 Results for MariTide, Its Weight-Loss Drug - Barron's
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.57%
1.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):